Previous 10 | Next 10 |
Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for its...
Organicell Regenerative Medicine (BPSR) has entered into an agreement with Oklahoma State University to evaluate Zofin for the treatment of respiratory diseases caused by virus infections of pandemic potential.Organicell will supply Oklahoma State University with its lead compound, Zofin, whi...
Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today announced that it has entered into an agreement with Oklahoma State University to evaluate Zofin™ for the treatment of ...
Organicell Regenerative Medicine ([[BPSR]] +13.1%) and Centers for Disease Control and Prevention ((CDC)) have entered into an agreement to conduct research on anti-inflammatory and anti-infective effectiveness of Zofin in experimental models of influenza infection.In the agreement, Orga...
Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today announced that it has entered into a Material Cooperative Research and Development Agreement with the Centers for Disease Cont...
Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today announced the publication of a peer-reviewed case report analyzing the clinical outcomes of Zofin treatment in three criticall...
Organicell Regenerative Medicine (BPSR) announces that the U.S. FDA has approved the Investigational New Drug application for its lead product, Zofin, in the treatment of patients diagnosed with chronic obstructive pulmonary disease ((COPD)).The approved trial design will be a double bl...
Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for its...
A Live Online Discussion on COVID-19 Long-Haulers Hosted by Organicell Regenerative Medicine, Inc. Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR) (the “ Company ” or “ Organicell ”), a clinical-stage biopharmaceutical company d...
Organicell Regenerative Medicine, Inc. (OTCMKTS:BPSR) (the “ Company ”), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies today announced that the Company and its therapeutic drug Zofin™ were recently featured in ...
News, Short Squeeze, Breakout and More Instantly...
Organicell Regenerative Medicine Inc Company Name:
BPSR Stock Symbol:
OTCMKTS Market:
Organicell Regenerative Medicine Inc Website:
Leading Therapeutics Research Company Begins New Era Common Stock to trade on OTCQB under the symbol "ZEOX" commencing March 5, 2024 FORT LAUDERDALE, FL / ACCESSWIRE / March 7, 2024 / ZEO ScientifiX, Inc . (OTCQB:ZEOX) (f/k/a Organicell Regenerative Medicine, Inc. - OTCQB:OCEL) today ...
Leading Therapeutics Research Company Begins New Era Common Stock to trade on OTCQB under the symbol "ZEOX" commencing March 5, 2024 FORT LAUDERDALE, FL / ACCESSWIRE / March 4, 2024 / ZEO ScientifiX, Inc . (OTCQB:ZEOX) (f/k/a Organicell Regenerative Medicine, Inc. - OTCQB: OCEL) today...
FORT LAUDERDALE, FL / ACCESSWIRE / November 27, 2023 / Organicell Regenerative Medicine Inc, (OTCQB:OCEL) ("Organicell" or the "Company"), today announced that it is implementing a 1-for-200 Reverse Split of the Company's common stock (the "Reverse Split") effective as of the close of business o...